Jazz Pharmaceuticals plc
JAZZ· Nasdaq
Released Feb 28, 2024, after the close
10-K filed Feb 28, 2024, 59 days after period end · 0001232524-24-000015
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $1.01B | $972.12M | $896.73M | $665.52M |
| Net Income | $94.15M | -$240.72M |
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR
| -$35.35M |
| $133.41M |
| EPS Diluted | — | — | — | $2.33 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.